6533b7ddfe1ef96bd1275344
RESEARCH PRODUCT
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
Elena De SantisMarcello BianchiniGabriele MelegariMattia RiefoloMariagrazia Del BuonoCalogero CammàNicola De MariaVeronica BernabucciAlessandra PivettiElisabetta BertelliniAngela CuratoloValentina ZuccaroAlessandra MelegariSilvio MalagutiFederico CasariFilippo SchepisRaffaele BrunoFabrizio TurriniBarbara LeiErica VillaDimitriy ArioliRosina Maria CritelliTommaso TrentiCiro CelsaGiovanni PinelliAntonia D'erricoDante RomagnoliSimone LasagniLucio BrugioniPietro TorricelliChiara GozziLucia CarulliLorenza Di MarcoIrene Cassanitisubject
medicine.medical_specialtyMultivariate analysis20CD34Risk Factors ...030204 cardiovascular system & hematologyGastroenterologyAntiviral AgentsAngiopoietin-203 medical and health sciences0302 clinical medicineRisk FactorsVascular BiologyInternal medicinemedicineHumans030212 general & internal medicineHospital MortalitySurvival rateProportional Hazards ModelsAntiviral AgentLungReceiver operating characteristicbusiness.industryProportional hazards modelSARS-CoV-2Interleukin-6Risk FactorHazard ratioCOVID-19HematologyBiomarker32Confidence intervalCOVID-19 Drug TreatmentHospitalizationSurvival RateAngiopoietin-2; Antiviral Agents; Area Under Curve; Biomarkers; COVID-19; Hospital Mortality; Hospitalization; Humans; Interleukin-6; Proportional Hazards Models; ROC Curve; Risk Factors; SARS-CoV-2; Survival Ratemedicine.anatomical_structureROC CurveArea Under Curvecardiovascular systemProportional Hazards ModelbusinessBiomarkersHumandescription
Key Points Three-day change in angiopoietin-2 levels predicts COVID-19 in-hospital mortality, whereas the 10-day trend is associated with chronic lung disability. Angiopoietin-2 may play an important pathogenic role in patients with COVID-19, and it could be a target for new treatments.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-01 |